AxoGen, Inc. — 2011 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2011. AxoGen develops and sells products for peripheral nerve repair, principally Avance Nerve Graft and AxoGuard Nerve Connector and Protector. On September 30, 2011, LecTec Corporation merged with AxoGen Corporation and changed its name to AxoGen, Inc. AxoGen Corporation was the accounting acquirer; accordingly, 2010 results and 2011 results through September 30 reflect AxoGen Corporation alone, with LecTec included only after the merger. The periods are therefore not fully comparable. The supplied filing does not provide clear standalone fourth-quarter financial results.
Financial and operating metrics
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $4.849 million | $3.004 million |
| Gross profit | $2.423 million; 50.0% gross margin | $1.626 million; 54.1% gross margin |
| Operating loss | $6.969 million | $4.482 million |
| Net loss | $9.219 million | $5.423 million |
| Net loss attributable to common shareholders | $10.248 million | $6.990 million |
| Cash used in operating activities | $7.079 million | $3.943 million |
| Cash and cash equivalents at year-end | $8.191 million | $1.799 million |
| Working capital at year-end | Approximately $8.8 million | Deficit of approximately $4.12 million |
| Long-term debt principal at year-end | $5.0 million | $8.430 million total debt reported |
Revenue increased 61.4%, which management attributed mainly to greater penetration of key accounts and new customers. Gross profit rose 49.0%, but margin declined amid $614,000 of expiring-inventory write-offs, a $214,000 raw-material obsolescence write-off, and higher processing, testing, travel, and temporary labor costs after Avance manufacturing resumed in January 2011. Sales and marketing expense increased 45.6% to $4.379 million; general and administrative expense rose 62.0% to $4.316 million; research and development expense rose to $697,000.
Cash increased by $6.392 million during 2011, primarily reflecting $7.202 million of cash acquired in the merger and financing proceeds; operations consumed $7.079 million. The September 2011 MidCap loan provided $5.0 million at 9.9% interest, secured by all company assets, with interest-only payments for the first 12 months and principal amortization thereafter. The loan includes minimum-revenue or cash-balance covenants. AxoGen stated that it believed cash resources were sufficient for the next 12 months, while also considering additional financing.
Material changes, outlook, and risks
- The merger materially changed the company’s capital structure and liquidity. Former AxoGen Corporation shareholders held approximately 56.8% of shares immediately after closing; former LecTec shareholders held approximately 39.4%. The 2011 financial statements also include significant merger-related accounting and financing effects.
- Management expected broader sales and marketing efforts to support longer-term revenue growth, but cautioned that near-term revenue growth could lag expense growth. No quantified revenue or earnings guidance is provided.
- Avance is distributed under an FDA enforcement-discretion transition plan while AxoGen pursues a biologics license. Continued sales depend on compliance with that plan and future regulatory action. FDA had approved the proposed phase 3 study design: a randomized, blinded comparative study of 150 subjects at 15 centers. Trial execution, results, costs, and eventual BLA approval remain uncertain.
- The business depends on three products, donor nerve-tissue supply, third-party processing and distribution, and the exclusive Cook Biotech supply arrangement for AxoGuard. AxoGen also identified reimbursement, product acceptance, competition, financing, debt covenants, and regulatory compliance as material risks.
- Management reported ineffective disclosure controls and ineffective internal control over financial reporting at year-end. A material weakness involved a contract recorded as an expense rather than a prepaid asset. A quarterly CFO review of significant contracts was introduced in the first quarter of 2012; management did not guarantee the weakness was fully remediated. The auditor expressed an unqualified opinion on the 2011 financial statements but did not attest to internal-control effectiveness.
- Unusual items include the 2011 inventory write-offs and merger-related conversion of preferred stock and convertible debt into common shares. The 2010 results included a $1.119 million gain from termination of a distribution agreement, which did not recur in 2011.
Key facts for investors to verify
- Review the merger’s effects on comparability, share count, acquired assets and liabilities, and reported 2011 cash and equity.
- Check subsequent progress, enrollment, cost, and results for the Avance phase 3 trial, and any FDA changes to its enforcement-discretion status or BLA pathway.
- Assess operating cash burn and financing needs against MidCap’s revenue and cash-balance covenants, including the potential need for additional capital.
- Monitor gross-margin recovery, inventory reserves and expirations, and whether sales growth can outpace sales, marketing, and administrative expense growth.
- Confirm remediation and testing of the disclosed material weakness and the effectiveness of financial reporting controls in subsequent filings.
- Verify continued access to donor tissue, LifeNet processing, and Cook Biotech’s AxoGuard products, as well as compliance with related agreements.